Drug Profile
AZD 6610
Alternative Names: AZD6610Latest Information Update: 31 Jul 2007
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antihyperlipidaemics
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Lipid metabolism disorders
Most Recent Events
- 31 Jul 2007 Discontinued - Phase-II for Diabetes mellitus in Europe (unspecified route)
- 31 Jul 2007 Discontinued - Phase-II for Lipid metabolism disorders in Europe (unspecified route)
- 01 Feb 2007 Phase-II clinical trials in Diabetes mellitus in Europe (unspecified route)